NBI-56418 is primarily investigated for its potential therapeutic applications, particularly in the field of endocrinology. It has been studied as a selective antagonist for the gonadotropin-releasing hormone (GnRH) receptor, which plays a critical role in regulating reproductive hormones. This makes it a candidate for treating conditions such as endometriosis, uterine fibroids, and hormone-dependent cancers like prostate and breast cancer. By modulating GnRH receptor activity, it may help reduce the production of sex hormones, thereby alleviating symptoms or slowing disease progression. Additionally, its targeted action could offer a more precise approach with potentially fewer side effects compared to broader hormonal therapies. Research is ongoing to explore its efficacy and safety in clinical settings.